Navigation Links
Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
Date:12/6/2010

BETHESDA, Md., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will host an investment community conference call beginning at 4:30 p.m. Eastern time on Thursday, December 9, to discuss results of the Company's Phase 3 trial with D-tagatose in Type 2 diabetes and to provide a business update.

Investors and other interested parties are invited to listen to the call by dialing (888) 563-6275 from the U.S. or (706) 634-7417 from outside the U.S.  The call also will be available on the Investors section of the Company's website at www.spherix.com.  Slides will accompany the conference call, and will be available in the Investors section of www.spherix.com.

A telephone replay of the conference call will be available for on-demand listening shortly after the completion of the call until 11:59 p.m. Eastern time on December 16, 2010 by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside the U.S., and entering access code 29797553.  A replay also will be available at www.spherix.com.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes.  Biospherics is actively seeking a pharma partner to continue the diabetes development while exploring D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
Breaking Biology News(10 mins):